U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT07546760) titled 'A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234' on March 11.
Brief Summary: The purpose of this study is to examine the safety and tolerability of AZD6234 and AZD9550 in participants with hepatic impairment and participants with normal hepatic function.
Study Start Date: March 20
Study Type: INTERVENTIONAL
Condition:
Hepatic Impairment
Intervention:
DRUG: AZD6234
Single subcutaneous dose of AZD6234 in participants from all groups
DRUG: AZD9550
Single subcutaneous dose of AZD9550 in participants from all groups
Recruitment Status: RECRUITING
Sponsor: AstraZeneca
Published by HT Dig...